Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s share price fell 2.5% during mid-day trading on Friday . The stock traded as low as $13.86 and last traded at $13.96, with a volume of 135,280 shares trading hands. The stock had previously closed at $14.32.

Several research firms have issued reports on ADMS. Mizuho upgraded shares of Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Monday, June 13th. Cowen and Company restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. Piper Jaffray Cos. restated an “overweight” rating and set a $44.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. Finally, Noble Financial restated a “buy” rating and set a $25.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 28th. Two equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.00.

The stock’s market capitalization is $307.66 million. The stock has a 50 day moving average of $14.74 and a 200-day moving average of $15.37.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its position in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.